

AstraZeneca PLC posted the following communication to its internal social media platform on February 26, 2021:

**WORKPLACE POST: MARC DUNOYER – GROWTH THROUGH INNOVATION GROUP**

**I SUPPORT**  
**RARE DISEASE DAY**  
**28 FEBRUARY 2021**  
#RAREDISEASEDAY RAREDISEASEDAY.ORG



This Sunday is globally recognised as Rare Disease Day. As we continue the planning process to bring together AstraZeneca and Alexion — two companies that share a dedication to delivering life-changing medicines to patients — this is an opportunity to pause and consider not only the community of rare disease patients we are preparing to serve, but also our future colleagues.

AstraZeneca and Alexion share a lot when it comes to values. We innovate for solutions, taking smart risks; and we follow the science, pushing the boundaries of what it can do. We are entrepreneurial, making choices to empower people and act with integrity. On a day like today, we recognise above all a commitment to serving patients and putting them first.

No patient can be left behind. Not the family member confronting cancer, nor the friend with heart disease, renal disease, asthma or COPD and not those living with a rare disease. The employees of both companies know this well and come to work each day on their behalf.

Our commitment to put patients at the heart of every decision is a value that resonates with each of us. It is also what I believe stands to underpin our success as we look to a future that builds on AstraZeneca and Alexion’s combined expertise. This is how we will drive innovation that delivers life-changing medicines for more patients.

I invite you to join me in acknowledging Rare Disease Day 2021. There is still much to do - only around 5% of the identified rare diseases have a specific drug approved and, while individually the patients in each disease are few, collectively rare diseases affect around 400 million people worldwide. The theme of the day - is “*Rare is many. Rare is strong. Rare is proud*” - a credo that Alexion employees exemplify, and we look forward to welcoming them pending the completion of our agreement.

**IMPORTANT ADDITIONAL INFORMATION**

---

## **Important Additional Information**

In connection with the proposed transaction, on February 19, 2021, AstraZeneca PLC (“AstraZeneca”) filed a registration statement on Form F-4 with the SEC, which includes a document that serves as a preliminary prospectus of AstraZeneca and a preliminary proxy statement of Alexion (the ‘proxy statement/prospectus’). The registration statement has not yet become effective. After the registration statement is declared effective by the SEC, Alexion intends to file with the SEC and mail to its stockholders a definitive proxy statement/prospectus. Investors and security holders of Alexion are urged to carefully read the entire registration statement and proxy statement/prospectus or proxy statement and other relevant documents filed or that will be filed with the SEC, because they contain or will contain important information. Investors and security holders will be able to obtain the registration statement and the proxy statement/prospectus or the proxy statement free of charge from the SEC’s website or from AstraZeneca or Alexion as described in the paragraphs below.

The documents filed by AstraZeneca with the SEC may be obtained free of charge at the SEC’s website at [www.sec.gov](http://www.sec.gov). These documents may also be obtained free of charge on AstraZeneca’s website at <http://www.astrazeneca.com> under the tab ‘Investors’.

The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at [www.sec.gov](http://www.sec.gov). These documents may also be obtained free of charge on Alexion’s internet website at <http://www.alexion.com> under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by contacting Alexion’s Investor Relations Department at [investorrelations@alexion.com](mailto:investorrelations@alexion.com).

## **Participants in the Solicitation**

Alexion, AstraZeneca and certain of their directors, executive officers and employees may be deemed participants in the solicitation of proxies from Alexion shareholders in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders of Alexion in connection with the proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus or proxy statement when it is filed with the SEC. Information about the directors and executive officers of Alexion and their ownership of Alexion shares is set forth in is set forth in Alexion’s Annual Report on Form 10-K/A, as previously filed with the SEC on February 16, 2021. Free copies of these documents may be obtained as described in the paragraphs above.

## **Forward-looking Information**

This announcement may include statements that are or may be deemed to be forward-looking statements. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “envisages”, “plans”, “projects”, “anticipates”, “targets”, “aims”, “expects”, “intends”, “may”, “will” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions and include, but are not limited to the ability of the parties to consummate the proposed acquisition on a timely basis or at all, the ability of the parties to satisfy the conditions precedent to consummation of the proposed acquisition, including the ability to secure the required regulatory approvals on the terms expected, at all or in a timely manner, the ability of AstraZeneca to successfully integrate Alexion’s operations, and the ability of AstraZeneca to implement its plans, forecasts and other expectations with respect to Alexion’s business after the completion of the proposed acquisition and realise expected synergies. Economic, competitive, governmental, technological and other factors that may affect AstraZeneca’s and Alexion’s operations are discussed in the section entitled “Risk Factors,” in each of AstraZeneca’s Annual Report on Form 20-F for the year ended 31 December 2020, and Alexion’s Annual Report on Form 10-K for the year ended 31 December 2020, in each case as amended by any subsequent filings made with the SEC. These forward-looking statements include all matters that are not historical facts and involve predictions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect AstraZeneca’s and Alexion’s current views with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to AstraZeneca’s or Alexion’s results of operations, financial position, liquidity, prospects, growth or strategies and the industries in which they operate. Forward-looking statements speak only as of the date they are made and cannot be relied upon as a guide to future performance. Save as required by law or regulation, AstraZeneca and Alexion disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements in this announcement that may occur due to any change in their expectations or to reflect events or circumstances after the date of this announcement.

---